Shots:
- Novo & Valo have expanded their partnership to discover & develop 9 more novel drugs for obesity, T2D & CV diseases, utilizing the former’s expertise in cardiometabolic diseases & Valo’s Opal computational platform plus mutual ability in human data & genetics
- As per the terms, Valo will get upfront, equity & near-term milestones of $190M, milestone payments for 20 drugs now as well as R&D funds & royalties, making it an aggregate of $4.6B
- The original deal of Sep 2023 included the development of 11 programs in exchange for ~$2.7B incl. upfront, R&D funding, milestones & royalties to Valo, leading to the identification of various novel targets
Ref: Novo Nordisk | Image: Novo Nordisk & Valo Health
Related News:- Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
